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KEEPING THE LABEL OUT OF THE CASE 
Mark Herrmann* and Pearson Bownas** 
INTRODUCTION 
The FDA approves prescription drugs and medical devices for only the 
specific uses indicated in the product labeling that the manufacturer submits 
in the approval process.  A physician may determine, however, that a use 
not indicated in the FDA-approved labeling—an ―off-label‖ use—would 
benefit a patient.  This Article argues that in medical malpractice cases in-
volving an off-label use, the product‘s label should not be admitted as evi-
dence of either the standard of care or the physician‘s alleged breach of that 
standard.   
I. OFF-LABEL USE EXPLAINED 
A. The FDA Approves Drugs and Devices for Only Specified “Intended 
Uses” 
Prescription drugs and certain medical devices cannot be sold and 
marketed in the United States unless the Food and Drug Administration 
(―FDA‖) approves them.1  The FDA approval regimes for drugs and medi-
cal devices require manufacturers to submit proposed labeling.2  This labe-
ling must include, among other things, indications of the product‘s intended 
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1
  See, e.g., 21 U.S.C. §§ 355 (drugs) (link), 360e (devices) (link) (2006).  The FDA drug and device 
approval regimes are discussed in detail in James M. Beck & Elizabeth D. Azari, FDA, Off-Label Use, 
and Informed Consent: Debunking Myths and Misconceptions, 53 FOOD & DRUG L.J. 71, 72–76 (1998). 
2
  E.g., 21 U.S.C. §§ 355(b)(1) (drugs), 360e(c)(1)(F) (devices); 21 C.F.R. § 314.50(c)(2)(i) (2008) 
(drugs) (link). 
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administration and dosage information.3  When the FDA approves a drug or 
device for sale and marketing, it does so only with respect to the indicated 
uses.4 
The FDA-approved label may also include ―contraindications‖ and 
―warnings and precautions.‖  A ―contraindication‖ is a ―situation[] in which 
the drug should not be used because the risk of use . . . clearly outweighs 
any possible therapeutic benefit.‖5  ―Warnings and precautions‖ are descrip-
tions of ―clinically significant adverse reactions . . . , other potential safety 
hazards . . . , limitations in use imposed by them . . . , and steps that should 
be taken if they occur,‖ as well as any other ―information regarding any 
special care to be exercised by the practitioner for safe and effective use of 
the drug . . . .‖6 
The analysis in this Article is limited to off-label uses that are not con-
traindicated, warned against, or identified by a precaution.  In a medical 
malpractice action involving a use that is contraindicated, for example, the 
FDA-approved label should be admissible because the FDA has analyzed 
that very use and concluded that the associated risk is unacceptable.7  By 
contrast, in an action involving a use as to which the FDA-approved label is 
silent, the FDA has not reached the same conclusion.  The FDA may simply 
not have considered the use being litigated, and the label listing the FDA-
approved uses is therefore irrelevant to determining whether the standard of 
care has been met. 
B. Off-Label Use Is Widespread 
Although the FDA approves drugs and medical devices for only the 
uses indicated in the product labeling, drugs and devices may have other, 
off-label uses that are beneficial.8  For example, physicians may use a prod-





  E.g., 21 C.F.R. §§ 201.56(d)(1) (link), 201.57(c)(2)–(3) (drugs) (link), 801.109 (devices) (link) 
(2008). 
4
  See, e.g., 21 U.S.C. §§ 355(d) (drugs), 360e(d)(1)(A)(ii), 360e(d)(2)(A)–(B) (devices).  Cf. 21 
C.F.R. § 201.57(c)(2)(ii) (―If there is a common belief that [a] drug may be effective for a certain use or 
if there is a common use of the drug for a condition, but the preponderance of evidence related to the use 
or condition shows that the drug is ineffective or that the therapeutic benefits . . . do not generally out-
weigh its risks, FDA may require [a statement] that there is a lack of evidence that the drug is effective 
or safe for that use or condition.‖). 
5
  21 C.F.R. § 201.57(c)(5). 
6
  Id. § 201.57(c)(6)(i)–(ii). 
7
  For the same reason, in a medical malpractice case involving an ―on-label‖ use, the prescribing 
physician should be allowed to offer the label as evidence that the FDA has considered that use and de-
termined it to be safe and effective.  See James R. Bird, Comment, Package Inserts for Prescription 
Drugs as Evidence in Medical Malpractice Suits, 44 U. CHI. L. REV. 398, 445–46 (1977).  This Article 
does not address what, if any, evidence plaintiffs may offer to try to offset that showing. 
8
  See, e.g., MayoClinic.com, Off-Label Drugs and Medical Devices: Get the Facts, 
http://www.mayoclinic.com/health/off-label/DI00088 (last visited Apr. 2, 2009) (link).  
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proved to treat.9  Or, physicians may prescribe a drug or device for a person 
outside the approved patient population.10  Physicians may also administer 
drugs by different routes, or in different doses or frequency, than approved 
by the FDA.11 
Off-label use of drugs and medical devices is common.  Between twen-
ty-five and sixty percent of all drug prescriptions written may be for off-
label uses.12  For some conditions, the percentage is even higher.  One re-
port estimates that sixty-five percent of all cancer drug use is off-label.13  
Other studies estimate that seventy percent of kidney dialysis patients use 
their equipment off-label,14 and that more than eighty percent of AIDS pa-
tients are receiving at least one off-label drug treatment.15 
II. THE FDA-APPROVED DRUG OR DEVICE LABEL SHOULD NOT BE 
ADMITTED IN AN OFF-LABEL USE CASE 
Virtually all medical treatments carry some degree of risk.16  When a 





  Id. 
10
  Id. 
11
  Id.; Lars Noah, Constraints on the Off-Label Uses of Prescription Drug Products, 16 J. PROD. & 
TOXICS LIAB. 139, 140–41 (1994). 
12
  Beck & Azari, supra note 1, at 80; Noah, supra note 11, at 139. 
13
  U.S. GEN. ACCOUNTING OFFICE, PROGRAM EVALUATION & METHODOLOGY DIV. NO. 91-14, 
OFF-LABEL DRUGS: REIMBURSEMENT POLICIES CONSTRAIN PHYSICIANS IN THEIR CHOICE OF CANCER 
THERAPIES 13 (1991) [hereinafter GAO REPORT], available at http://archive.gao.gov/d18t9/144933.pdf 
(link).  See also, e.g., P. G. Casali, The Off-Label Use of Drugs in Oncology: A Position Paper by the 
European Society for Medical Oncology (ESMO), 18 ANNALS ONCOLOGY 1923, 1923 (2007) (internal 
citations omitted) (―The off-label use of drugs in oncology has been estimated to reach 50%, or even 
more.‖) (link). 
14
  FDA and Dialyzer Makers Spar Over Device Reuse, FOOD & DRUG LETTER, Apr. 8, 1994, at 3. 
15
  Carol L. Brosgart et al., Off-Label Drug Use in Human Immunodeficiency Virus Disease, 12 J. 
ACQUIRED IMMUNE DEFICIENCY SYNDROMES & HUMAN RETROVIROLOGY 56, 57–58 (1996).  Other 
conditions with standard off-label use treatments have included heart and circulatory disease, osteoporo-
sis, spinal injuries requiring fusion surgery, and incontinence.  Beck & Azari, supra note 1, at 80 & n.80.  
Because historically drugs were rarely tested on children, the FDA rarely had the data necessary to ap-
prove drugs for use on children.  Thus, as many as eighty percent of prescriptions written for children 
were for off-label uses.  See, e.g., Lauren Hammer Breslow, Note, The Best Pharmaceuticals for Child-
ren Act of 2002: The Rise of the Voluntary Incentive Structure and Congressional Refusal to Require 
Pediatric Testing, 40 HARV. J. ON LEGIS. 133, 135–44 (2003) (analyzing reasons for the scarcity of pe-
diatric clinical drug trials) (link).  Since 1997, Congress has passed a series of measures to increase pe-
diatric testing and labeling of drugs and devices.  See, e.g., Food and Drug Administration 
Modernization Act of 1997, Pub. L. No. 105-115, § 111, 111 Stat. 2296, 2305–09 (1997) (codified as 
amended at 21 U.S.C. § 355a (2006) (link)) (link).  These measures, however, have been voluntary, sub-
ject to waiver, and/or applied primarily to new drugs and devices, and some of the provisions are rela-
tively new.  Thus, it is not clear that they have significantly affected the frequency of off-label pediatric 
uses. 
16
  See, e.g., U.S. Food and Drug Administration, Information for Consumers: Side Effects, 
http://www.fda.gov/cder/info/consumer_safety.htm (last visited Apr. 2, 2009) (―All medicines have ben-
efits and risks.‖) (link). 
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the course of that treatment, the patient may sue and contend that the off-
label use was, in and of itself, a violation of the standard of care—that such 
use was negligent.17  Undoubtedly, the patient will try to introduce the 
drug‘s or device‘s label as evidence of the physician‘s alleged negligence. 
One recent case reported that ―[v]irtually every court addressing [the] 
question has concluded that the drug‘s labeling and PDR reference are rele-
vant to the standard of care issue.‖18  According to that court, ―[s]everal ju-
risdictions, believing drug manufacturers to be uniquely knowledgeable 
about the proper use of their products, have held that a drug‘s labeling or its 
parallel PDR reference amounts to prima facie evidence of the standard of 
care as far as the use of that drug is concerned.‖19  Nevertheless, ―a majority 
of jurisdictions have determined that a prescription drug‘s labeling or paral-
lel PDR reference is admissible to prove the standard of care, but only if the 
plaintiff also introduces other expert testimony regarding the standard of 
care.‖20 
Both rationales for admitting drug and device labeling in off-label use 
cases are incorrect.  FDA-approved drug and device labeling is not relevant 
evidence of the standard of medical care.  And even if the labeling offered 
some evidence of that standard, the risk of confusion, prejudice, and undue 
waste of time would substantially outweigh that marginal relevance. 
A. The FDA-Approved Label Is Not Relevant Evidence of the Standard of 
Care 
The plaintiff in a medical malpractice action must prove that the de-
fendant physician failed to meet the standard of care, which in most juris-
dictions is the level of skill and knowledge possessed by medical 
professionals in the same or a similar community.21  Only evidence that is 
relevant to establishing the standard of care should be admitted in the plain-
tiff‘s case.  The FDA-approved label is not relevant evidence of the stan-





  See Paul D. Rheingold & David B. Rheingold, Offense or Defense? Managing the Off-Label Use 
Claim, 37 TRIAL, Mar. 2001, at 52, 52–55. 
18
  Richardson v. Miller, 44 S.W.3d 1, 15 (Tenn. Ct. App. 2000) (link).  ―PDR‖ refers to the 
PHYSICIANS‘ DESK REFERENCE, ―an encyclopedia of medications written and published annually and 
provided to all practicing physicians.‖  Id. at 11.  The PDR contains the same information drug manufac-
turers are required to include in their package insert labeling.  Id.; see 21 C.F.R. § 201.100(c)–(d) (2008) 
(link). 
19
  Richardson, 44 S.W.3d at 16 (citing cases).   
20
  Id.  The treatment of drug and device labels in medical malpractice cases is also discussed in 
Bird, supra note 7. 
21
  See, e.g., RESTATEMENT (SECOND) OF TORTS § 299A (1965) (―[O]ne who undertakes to render 
services in the practice of a profession or trade is required to exercise the skill and knowledge normally 
possessed by members of that profession or trade in good standing in similar communities.‖). 
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1. The FDA and Manufacturers Are Not Local Medical 
Practice Standard Bearers 
Drug and device labeling is a creature of federal regulatory law.  The 
FDA, the creature‘s master, has repeatedly said it does not regulate the 
practice of medicine.22  Accordingly, the FDA has repeatedly confirmed that 
the absence of a particular use from a drug‘s or device‘s approved label has 
no legal effect on a physician‘s ability to put the drug or device to that use: 
 
 In a 1972 rulemaking proposal, the FDA stated that a 
―physician may, as part of the practice of medicine, 
lawfully prescribe a different dosage for his patient, or 
may otherwise vary the conditions of use from those 
approved in the package insert . . . .‖23  Thus, ―labeling 
is not intended either to preclude the physician from 
using his best judgment in the interest of the patient, or 
to impose liability if he does not follow the package 
insert.‖24 
 In a 1982 Drug Bulletin, the FDA stated that federal 
law ―does not . . . limit the manner in which a physician 
may use an approved drug.  Once a product has been 
approved for marketing, a physician may prescribe it 
for uses or in treatment regimens or patient populations 
that are not included in approved labeling.‖25 
 In a January 2009 industry guidance document, the 
FDA stated that ―[o]nce a drug or medical device has 
been approved or cleared by FDA, generally, health-





  See, e.g., More Information for Better Patient Care: Hearing on S. 1477 Before the S. Comm. on 
Labor and Human Resources, 104th Cong. app. at 82 (1996) (statement of William B. Schultz, Deputy 
Comm‘r for Policy, Food & Drug Admin.), available at http://www.fda.gov/ola/1996/s1447.html (ar-
guing that ―[t]he legislative history of the Federal Food, Drug, and Cosmetic Act indicates that Congress 
did not intend FDA to interfere with the practice of medicine,‖ and that ―once a drug is approved for 
marketing, FDA does not generally regulate how, and for what uses, physicians prescribe that drug‖) 
(link).  The United States Supreme Court has reached the same conclusion.  See Buckman Co. v. Plain-
tiffs‘ Legal Comm., 531 U.S. 341, 350 (2001) (stating that ―‗off-label‘ usage of medical devices (use of 
a device for some other purpose than that for which it has been approved by the FDA) is an accepted and 
necessary corollary of the FDA‘s mission to regulate in this area without directly interfering with the 
practice of medicine‖) (link). 
23
  Legal Status of Approved Labeling for Prescription Drugs; Prescribing for Uses Unapproved by 
the Food and Drug Administration, 37 Fed. Reg. 16,503, 16,503 (proposed Aug. 15, 1972) (link). 
24
  Id. at 16,504.  Notwithstanding this clear statement that an off-label use is not unlawful, the FDA 
also said in the same document that ―labeling, along with medical articles, tests, and expert opinion, may 
constitute evidence of the proper practice of medicine . . . .‖  Id. (emphasis added). 
25
  12 FDA DRUG BULL., Apr. 1982, at 1, 5 (link). 
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product for uses or treatment regimens that are not in-
cluded in the product‘s approved labeling . . . .‖26 
 
Congress, too, recognizes that off-label uses are not per se improper.  
Federal law provides that ―[n]othing in [the Federal Food, Drug, and Cos-
metic Act] shall be construed to limit or interfere with the authority of a 
health care practitioner to prescribe or administer any legally marketed de-
vice to a patient for any condition or disease within a legitimate health care 
practitioner-patient relationship.‖27  Also, Congress requires government in-
surance programs to pay for certain off-label uses.28 
Unsurprisingly, federal29 and state courts30 are in accord.  And, like 
Congress, many state legislatures have at least tacitly approved certain off-
label uses by requiring insurance companies to cover them.31 
These positions make sense because the FDA‘s information-gathering 





  FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: GOOD REPRINT PRACTICES FOR THE 
DISTRIBUTION OF MEDICAL JOURNAL ARTICLES AND MEDICAL OR SCIENTIFIC REFERENCE 
PUBLICATIONS ON UNAPPROVED NEW USES OF APPROVED DRUGS AND APPROVED OR CLEARED 
MEDICAL DEVICES 3 (2009) [hereinafter FDA, UNAPPROVED NEW USES REPRINT GUIDANCE], available 
at http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0053-gdl.pdf (link).  It is particularly 
anomalous to admit the drug‘s labeling taken from the PDR, as some courts have done, because that 
publication recognizes that the FDA-approved labeling it contains does not ―limit the manner in which a 
physician may use an approved drug.‖  Foreword to PHYSICIANS‘ DESK REFERENCE (62d ed. 2008). 
27
  21 U.S.C. § 396 (2006) (link). 
28
  E.g., 42 U.S.C. § 1395x(t)(2)(A)–(B) (2006) (including off-label indications supported by speci-
fied medical publications in Medicare reimbursement program) (link). 
29
  See, e.g., Buckman Co. v. Plaintiffs‘ Legal Comm., 531 U.S. 341, 350 (2001); Ortho Pharm. 
Corp. v. Cosprophar, Inc., 32 F.3d 690, 692 (2d Cir. 1994) (―[T]he FDA permits doctors to prescribe 
drugs for ‗off-label‘ uses.‖) (link); Weaver v. Reagen, 886 F.2d 194, 198 (8th Cir. 1989) (―[T]he fact 
that FDA has not approved labeling of a drug for a particular use does not necessarily bear on those uses 
of the drug that are established within the medical and scientific community as medically appropriate.‖) 
(link). 
30
  See, e.g., Sita v. Long Island Jewish-Hillside Med. Ctr., 803 N.Y.S.2d 112, 114 (N.Y. App. Div. 
2005) (―Although marketing and promotion of the [treatment] system was not approved by the [FDA] 
for treating the injured plaintiff‘s condition, this does not prevent a physician from using the system in 
an ‗off-label‘ manner.‖) (link); State Bd. of Regents for the Healing Arts v. McDonagh, 123 S.W.3d 
146, 150 (Mo. 2003) (―[N]on-FDA-approved, or ‗off-label,‘ use of medications by physicians is not 
prohibited by the FDA and is generally accepted in the medical profession.‖) (link); Southard v. Temple 
Univ. Hosp., 781 A.2d 101, 104 (Pa. 2001) (―The FDA does not preclude off-label use of medical de-
vices.  To the contrary, while the FDA regulates the marketing and labeling of medical devices, it does 
not purport to interfere with the practice of medicine.‖). 
31
  E.g., ALA. CODE § 27-1-10.1 (LexisNexis 2007) (link); CAL. INS. CODE § 10123.195(a) (West 
2005) (link); CONN. GEN. STAT. ANN. §§ 38a-492b(a) (link), 38a-518b(a) (link) (West 2007); FLA. 
STAT. ANN. § 627.4239(2)(a) (West 2005) (link); 5 ILL. COMP. STAT. ANN. 375/6.4 (West 2005) (link); 
MICH. COMP. LAWS ANN. §§ 500.3406e (link), 500.3616a (link) (West 2002); MO. ANN. STAT. 
§§ 376.429(3) (link), 376.1361(11) (link) (West 2002 & Supp. 2009); N.H. REV. STAT. ANN. §§ 415:6-g 
(link), 415:18-j (link) (LexisNexis 2009); N.J. STAT. ANN. § 26:1A-36.9 (West 2007) (link); OHIO REV. 
CODE ANN. § 1751.66(A) (West Supp. 2008) (link); OKLA. STAT. ANN. tit. 63, §§ 1-2604, 1-2605 (West 
2004) (link); R.I. GEN. LAWS § 27-55-2 (2008) (link); VA. CODE ANN. § 38.2-3407.5 (2007) (link). 
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on only data that exists when approval is sought and for indications that the 
manufacturer chooses to pursue.32  A physician, by contrast, has ―access to 
new information on drugs through the medical literature, scientific meet-
ings, postgraduate courses, and professional contacts with colleagues.‖33  
Thus, ―[t]he package insert is not intended under the law to serve as a total-
ly current repository of all such information.‖34 
Drug and device manufacturers likewise are not attempting to define 
the standard of care.  They prepare labeling to get their products approved 
and to market.35  Thus, courts have found that ―[t]he purposes behind the 
[information a drug or device manufacturer provides about a product] rend-
er its contents ill-suited to serve as prima facie evidence of a standard of 
care; they seek to cover a wide range of concerns not always directed at a 
diagnosis and course of treatment.‖36 
2. There Are Many Reasons, Unrelated to Standards of 
Care, Why a Use May Not Be Indicated “On Label” 
The uses indicated in a drug‘s or device‘s FDA-approved labeling are 
not evidence that another use is outside the standard of care because there 
are compelling reasons why a widely accepted and demonstrably safe and 
effective use for a drug or device may be omitted.  For one, science ad-





  An FDA official has observed that, in some cases, the existing data regarding an off-label use is 
sufficiently comprehensive that the use ―could be approved by FDA if the sponsor would simply com-
pile the existing literature and submit it to us.‖  More Information for Better Patient Care: Hearing on S. 
1477 Before the S. Comm. on Labor & Human Res., 104th Cong. app. at 88 (1996) (statement of Wil-
liam B. Schultz, Deputy Comm‘r for Policy, Food & Drug Admin.), available at 
http://www.fda.gov/ola/1996/s1447.html (link).  
33
  Labeling for Prescription Drugs Used in Man: Proposed Format of Prescription-Drug Advertise-
ments, 40 Fed. Reg. 15,392, 15,394 (proposed Apr. 7, 1975). 
34
  Id.  Courts have also recognized the limitation.  See, e.g., United States v. Evers, 453 F. Supp. 
1141, 1149 (M.D. Ala. 1978) (―It is well-recognized that a package insert may not contain the most up-
to-date information about a drug . . . .‖) (link).  After the FDA approves a drug or device for an indicated 
use, it continues to monitor adverse events and may withdraw its approval if it determines that the drug 
or device is not safe for that use.  See, e.g., 21 C.F.R. §§ 314.80 (link), 314.150 (link) (2008).  The FDA 
will not, however, act to approve a new use unless the manufacturer submits the appropriate supporting 
information.  See supra note 32 and accompanying text. 
35
  E.g., Arnold v. Lee, No. 05-0651, 2006 WL 1410161, at *4 (Iowa Ct. App. May 24, 2006) (stat-
ing that ―the manufacturer has its own reasons for the information contained in the package inserts,‖ 
which ―are not limited to altruism or the education of the medical community‖).  See also Bird, supra 
note 7, at 416 (noting that the American Medical Association ―has repeatedly alleged that inserts are an 
inadequate standard for medical practice, pointing to the inconsistent purposes served by the docu-
mentadvertising for the manufacturer, regulation by the government, and information for the doctor‖). 
36
  Spensieri v. Lasky, 723 N.E.2d 544, 548 (N.Y. 1999) (internal citations omitted) (link). 
37
  E.g., Sidney A. Shapiro, Limiting Physician Freedom to Prescribe a Drug for Any Purpose: The 
Need for FDA Regulation, 73 NW. U. L. REV. 801, 811 (1978) (observing that off-label uses ―are unlike-
ly ever to be eliminated since there is an unavoidable lag between the time a new use for a drug is dis-
covered and the time that use is approved by the FDA‖).  Indeed, a manufacturer may not even start the 
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fits of an off-label use and share those benefits with others, through jour-
nals, presentations, and professional associations, long before the FDA ap-
proves the use.38 
Even if science and regulation advanced at the same rate, however, 
there are several reasons why much standard of care medicine would still 
not be reflected in drug or device labeling.39  First, ―[b]ecause of the time 
and expense of obtaining FDA approval of new uses for an already ap-
proved drug, drug manufacturers frequently do not voluntarily request FDA 
approval for a new use unless the change in the labeling will pay for itself 
in increased profits.‖40  Self-funding label changes are particularly unlikely 
when the drug‘s or device‘s patent is nearing expiration (thus exposing the 
drug or device to generic competition)41 and when the market for the off-
label use is small.42 
Second, drug and device manufacturers have limited research and de-
velopment dollars, and they may decide those dollars are better spent pur-
suing groundbreaking new therapies than seeking approval for new uses of 
products already being sold.43 
Third, limited resources may also make it difficult for manufacturers to 
find researchers willing to perform the clinical trials necessary to obtain 
FDA approval for the new use.  When the off-label use to be investigated is 
already widely accepted, researchers may find the investigation to be ―at 
least uninteresting, if not a waste of time.‖44 
Fourth, when the off-label use is already widely accepted as beneficial, 
the availability of researchers may also be limited by ethical constraints: 
―The conflict between the patient‘s therapeutic needs and the needs of the 
experimental trial [such as supplying placebos to the control group of af-
flicted subjects] poses ethical problems which may deter a physician from 
acting as an investigator.‖45 
                                                                                                                           
testing required to support FDA approval for a new use until after that use becomes the medically ac-
cepted standard.  Id.   
38
  See 12 FDA DRUG BULL., supra note 25, at 5. 
39
  See Stuart L. Nightingale, Off-Label Use of Prescription Drugs, 68 AM. FAM. PHYSICIAN 425, 
425–26 (2003) (link).  
40
  Richardson v. Miller, 44 S.W.3d 1, 12 (Tenn. Ct. App. 2000).  The General Accounting Office 
similarly observed that, when an off-label use is proven effective, ―the manufacturer can ask the FDA to 
make a formal change in the label that would reflect the expanded benefits of the drug.  However, repre-
sentatives from the pharmaceutical industry characterize this process as cumbersome, time-consuming, 
and expensive compared to the payoff for a company.‖  GAO REPORT, supra note 13, at 11 n.2. 
41
  See GAO REPORT, supra note 13, at 11 n.2. 
42
  See, e.g., Beck & Azari, supra note 1, at 80 n.80 (observing that ―[m]ost diseases afflicting fewer 
than 200,000 Americans‖ do not have FDA-labeled treatments). 
43
  Noah, supra note 11, at 145. 
44
  David A. Kessler, Regulating the Prescribing of Human Drugs for Nonapproved Uses Under the 
Food, Drug, and Cosmetic Act, 15 HARV. J. ON LEGIS. 693, 730 (1978). 
45
  Id.; see Jennifer A. Henderson & John J. Smith, Realizing the Potential for Biomarkers in Imag-
ing: Background and Legal Basis, 60 FOOD & DRUG L.J. 511, 515–16 (2005) (link). 
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Fifth, when the off-label use is already the standard of care for a par-
ticular disease or condition, it may be difficult to find a traditional control 
group, because most people afflicted with the disease or condition are al-
ready receiving the off-label treatment that is to be studied.46  
Sixth, if a manufacturer seeks approval for a new use, the FDA may 
choose to revisit the entire label.47  If the original label resulted from com-
promise between the manufacturer and the FDA, the manufacturer may 
wish not to reopen these negotiations.48 
Congress‘s efforts to induce manufacturers to seek FDA approval for 
off-label uses have not entirely cured these disincentives.  Although manu-
facturers are not permitted to market a drug for off-label use, the 1997 Food 
and Drug Administration Modernization Act allowed manufacturers to dis-
seminate certain scientific literature about an off-label use if the manufac-
turer had submitted, or certified that it would submit, a supplemental 
application seeking FDA approval for the use.49  The statute permitted man-
ufacturers to disseminate information without submitting, or promising to 
submit, a supplemental application, however, when it would be ―economi-
cally prohibitive . . . to conduct the studies necessary to submit a supple-
mental application for the [off-label] use.‖50  And, of course, manufacturers 
willing to rely on the medical community to spread the word about a partic-
ular off-label use would not subject themselves to this rule.  In any case, 
this provision and its implementing regulations expired in 2006.51  The FDA 
recently issued an industry guidance statement on the topic, which suggests 
that manufacturers may continue to disseminate certain types of literature 
about off-label uses, but without requiring manufacturers to submit, or 
promise to submit, a supplemental application for FDA approval of those 
uses.52 
Thus, there are many reasons—unrelated to the standard of care—why 
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3. Off-Label Use May Actually Be the Standard of Care 
An FDA-approved label should not be admissible as evidence of the 
standard of care because the FDA, as well as leading medical authorities 
and courts, have recognized that an off-label use may well be the safest, 
most effective, state-of-the-art treatment.  Indeed, the off-label use may it-
self constitute the standard of care.  For example: 
 
 The FDA, in an industry guidance document, which 
represents the FDA‘s ―current thinking,‖ observes that 
―off-label uses or treatment regimens . . . may even 
constitute a medically recognized standard of care.‖53 
 The General Accounting Office‘s Director of Health 
Services Quality and Public Health Issues testified to a 
congressional subcommittee that ―a drug given off-
label may have been proven to be safer and more bene-
ficial than any drug labeled for that disease.‖54 
 Courts have found that ―[b]ecause the pace of medical 
discovery runs ahead of the FDA‘s regulatory machi-
nery, the off-label use of some drugs is frequently con-
sidered to be ‗state-of-the-art‘ treatment.‖  Indeed, ―[i]n 
some circumstances, an off-label use of a particular 
drug or device may even define the standard of care.‖55 
 According to the vice president of the American Medi-
cal Association, ―‗[i]n some cases, if you didn‘t use the 
drug in the off-label way you‘d be guilty of malprac-
tice.‘‖56 
 
Neither the FDA nor manufacturers intend to set the standard of care 
for medical malpractice purposes in drug and device labeling.  There are 
many reasons why uses that conform to the standard of care may be omitted 
from an FDA-approved label.  An FDA-approved label‘s silence as to a par-
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B. Admitting Drug and Device Labels Poses a Substantial Risk of 
Prejudice and Confusion 
Some courts have admitted FDA-approved drug and device labels as 
―some evidence‖ of the standard of care.57  For all the reasons explained 
above, those courts decided wrongly.  But even if FDA-approved labels had 
some evidentiary value in an off-label use case, that value would be out-
weighed by the significant risk of prejudice, confusion, and time-wasting 
that its admission would cause.58   
Indeed, just the terminology associated with off-label use poses the risk 
of prejudice and confusion.  Uses of drugs and devices not indicated on the 
drug‘s or device‘s labeling can be called ―unapproved,‖ ―unlabeled,‖ ―off-
label,‖ or ―extra-label.‖59  As the FDA itself recognized, ―[t]he term ‗unap-
proved uses‘ is, to some extent, misleading.  It includes a variety of situa-
tions ranging from unstudied to thoroughly investigated drug uses.‖60 
Consumer survey data confirm these risks.  According to a 2006 Wall 
Street Journal/Harris Interactive Health-Care Poll, fifty percent of adults 
in the United States (out of 3,018 surveyed) believe that, once a drug is ap-
proved by the FDA, a physician may prescribe the drug for only the FDA-
approved uses; another twenty-five percent were unsure.61  A trial laden 
with references to ―unapproved‖ uses would also inappropriately pander to 
jurors‘ views that off-label uses should not be permitted.  The same survey 
found that nearly half of respondents believe that physicians should not be 
allowed to prescribe a drug to treat diseases other than the diseases indi-
cated in the FDA-approved labeling for that drug.62  More respondents disa-
greed than agreed that ―[d]octors should be allowed to decide which 
prescription drug treatments to use with their patients regardless of what 
diseases they have or have not been approved for by the FDA.‖63  And six-
ty-two percent of respondents agreed that ―[p]rescription drug use for unap-
proved medical conditions should be prohibited except as part of the 
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These 2006 results confirm the results of a similar survey conducted in 
2004.65  Together, these surveys demonstrate that public misconception and 
distrust about off-label use is common and deep-seated. 
At least one court has, without the benefit of this type of survey data, 
concluded that the risk of confusion and prejudice could be adequately ad-
dressed through cross-examination and jury instructions.66  But if either of 
those were a panacea, then Federal Rule of Evidence 403 and its state law 
analogues, which exclude evidence likely to confuse and more prejudicial 
than probative, would not be necessary.  And the Harris Poll results demon-
strate the sort of ―widely held prejudice‖67 that courts have relied on to ex-
clude evidence under those rules.68 
Evidence that a particular use is off-label should also be excluded to 
avoid wasting time.69  Consider, for example, the case in which the plaintiff 
relies exclusively on the off-label nature of the use as proof of malpractice.  
If the physician‘s expert witness will testify that the off-label use was, in 
fact, the state-of-the-art treatment, and the judge will instruct the jury that 
an off-label use is not negligence per se, then the label would come in, only 
to be refuted by evidence that the physician and court hope will erase the 
label‘s effect on the jurors.  This wastes time and may breed confusion. 
Even if the plaintiff offered expert testimony in addition to the product 
label to establish the standard of care, admitting the label would waste time.  
In a field such as oncology, for example,70 the plaintiff would offer the label 
and the defense expert would testify that most treatments are off-label and 
so the uses indicated on the label are far removed from the standard of care.  
The physician in that type of case may or may not have committed malprac-
tice, but admitting the label consumes time without giving the jury useful 
information. 
CONCLUSION 
Drug and device labels reflect competing regulatory and commercial 
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the medical state-of-the-art.  The FDA has repeatedly recognized that off-
label uses are generally allowed and may be the standard of care.  Thus, the 
absence of a use from an FDA-approved label proves nothing about the 
standard of care or a physician‘s deviation from (or adherence to) that stan-
dard when he or she employs that off-label use.  Allowing plaintiffs in off-
label medical malpractice cases to introduce evidence that the physician‘s 
use was ―off-label,‖ ―unapproved,‖ or ―unauthorized‖ unfairly appeals to 
commonly held misconceptions about the effect of FDA approval.  Defen-
dants in these types of cases must know and use all the arguments available 
to oppose the admission of this off-label evidence, and courts must be made 
more aware of this evidence‘s prejudicial dangers. 
